Results 1 to 10 of about 46,034 (246)

Secondary polycythemia in chronic obstructive pulmonary disease: prevalence and risk factors

BMC Pulmonary Medicine, 2021
Background Secondary polycythemia is associated with cigarette smoking and chronic obstructive pulmonary disease (COPD). However, the prevalence of polycythemia in COPD and the contributing risk factors for polycythemia in COPD have not been extensively ...
Jingzhou Zhang, Dawn L. DeMeo, Edwin K. Silverman, Barry J. Make, R. Chad Wade, J. Michael Wells, Michael H. Cho, Brian D. Hobbs   +7 more
doaj   +2 more sources

Current Management Strategies for Polycythemia Vera and Essential Thrombocythemia

Blood Reviews, 2020
Polycythemia vera (PV) and essential thrombocythemia (ET) are myeloproliferative neoplasms characterized by increased rate of cardiovascular events, a varying burden of symptoms, and an intrinsic risk of evolution to secondary forms of myelofibrosis and ...
Alessandro Maria Vannucchi, Paola Guglielmelli   +1 more
exaly   +2 more sources

Prevalence and diagnostic performance of iron deficiency in polycythemia

Hematology, 2023
Introduction Several observations have shown that patients with polycythemia have iron deficiency. Our objectives were to report the prevalence of iron deficiency and to evaluate the diagnostic performance of serum ferritin in polycythemia vera.Patients ...
Rova Malala Fandresena Randrianarisoa, Herveat Ramanandafy, Alexandre Mania, Hélène Monjanel, Sébastien Trouillier   +4 more
doaj   +1 more source

Polycythemia vera: 2024 update on diagnosis, risk‐stratification, and management

American journal of hematology/oncology, 2023
Polycythemia vera (PV) is a JAK2‐mutated myeloproliferative neoplasm characterized by clonal erythrocytosis; other features include leukocytosis, thrombocytosis, splenomegaly, pruritus, constitutional symptoms, microcirculatory disturbances, and ...
A. Tefferi, T. Barbui
semanticscholar   +1 more source

JAK2V617F allele burden in polycythemia vera: burden of proof

Blood, 2023
Visual ...
A. Moliterno, H. Kaizer, B. Reeves
semanticscholar   +1 more source

Long-term outcomes of polycythemia vera patients treated with ropeginterferon Alfa-2b

Leukemia, 2022
TO THE EDITOR: Interferon alfa not only restores normal blood cell counts in patients with polycythemia vera (PV) but can diminish the mutant JAK2 V617F allele burden [1 – 3].
J. Kiladjian, C. Klade, P. Georgiev, D. Krochmalczyk, L. Gercheva-Kyuchukova, M. Egyed, P. Dulíček, Á. Illés, H. Pylypenko, L. Sivcheva, J. Mayer, V. Yablokova, K. Krejcy, V. Empson, H. Hasselbalch, R. Kralovics, H. Gisslinger   +16 more
semanticscholar   +1 more source

Haemoglobin Olympia {β Codon 20 (B2) G→A, Val→Met}: A Silent Haemoglobin Variant [PDF]

Journal of Clinical and Diagnostic Research, 2021
High oxygen affinity haemoglobin variants are rare and often underdiagnosed in persistent erythrocytosis with no apparent aetiology. Here the author present a 29-year-old Indian male patient with a long-standing history of erythrocytosis which was ...
Abhay A Bhave, Lakshmi Iyer, Nawal Kazi, Manju Gorivale, Anita Nadkarni   +4 more
doaj   +1 more source

Ropeginterferon versus Standard Therapy for Low-Risk Patients with Polycythemia Vera.

NEJM Evidence, 2023
Ropeginterferon for Patients with Polycythemia VeraPatients with low-risk polycythemia vera were randomly assigned to receive ropeginterferon alfa-2b and phlebotomy or phlebotomy alone.
T. Barbui, A. Vannucchi, V. De Stefano, A. Carobbio, A. Ghirardi, Greta Carioli, A. Masciulli, E. Rossi, F. Ciceri, M. Bonifacio, A. Iurlo, F. Palandri, G. Benevolo, F. Pane, A. Ricco, G. Carli, M. Caramella, D. Rapezzi, C. Musolino, S. Siragusa, E. Rumi, A. Patriarca, N. Cascavilla, B. Mora, E. Cacciola, C. Mannarelli, G. G. Loscocco, P. Guglielmelli, F. Gesullo, S. Betti, F. Lunghi, L. Scaffidi, C. Bucelli, N. Vianelli, M. Bellini, M. Finazzi, G. Tognoni, A. Rambaldi   +37 more
semanticscholar   +1 more source

Diagnosis and genetic analysis of polycythemia in children and a novel EPAS1 gene mutationWhat is knownWhat is new?

Pediatrics and Neonatology, 2022
Background: Unlike in adults, there is no consensus on management and diagnosis of polycythemia in children. This study aims to evaluate the diagnosis and verify the algorithm in children with polycythemia.
Hatice Mine Cakmak, Omer Kartal, Ayca Kocaaga, Yasar Bildirici   +3 more
doaj   +1 more source

A randomized phase 3 trial of interferon-α vs hydroxyurea in polycythemia vera and essential thrombocythemia

Blood, 2022
Therapy for essential thrombocythemia (ET) and polycythemia vera (PV) is aimed at reducing thrombotic risk through normalizing blood counts. Mascarenhas et al report on a randomized trial of hydroxyurea (HU) vs pegylated interferon α (PEG) in 168 ...
J. Mascarenhas, H. Kosiorek, J. Prchal, A. Rambaldi, Dmitriy P. Berenzon, A. Yacoub, C. Harrison, M. McMullin, A. Vannucchi, J. Ewing, C. O'Connell, J. Kiladjian, A. Mead, E. Winton, D. Leibowitz, V. De Stefano, M. Arcasoy, C. Kessler, R. Catchatourian, D. Rondelli, R. Silver, A. Bacigalupo, A. Nagler, M. Kremyanskaya, M. Levine, J. A. Arango Ossa, E. McGovern, L. Sandy, M. Salama, V. Najfeld, J. Tripodi, N. Farnoud, A. Penson, R. Weinberg, L. Price, J. Goldberg, T. Barbui, R. Marchioli, G. Tognoni, R. Rampal, R. Mesa, A. Dueck, R. Hoffman   +42 more
semanticscholar   +1 more source